Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20116129 | 0.87 | TUBB4A (0.50) | LDHASMN1; SMN2 | |
| SCHEMBL30552726 | 0.87 | TUBB4A (0.50) | LDHASMN1; SMN2 | |
| SCHEMBL20117147 | 0.85 | USP7 (0.45) | SMN1; SMN2SCD5USP7KIT | |
| SCHEMBL26999735 | 0.84 | TUBB4A (0.47) | LDHASMN1; SMN2 | |
| SCHEMBL22358021 | 0.83 | USP7 (0.43) | SMN1; SMN2SCD5USP7 | |
| SCHEMBL22357963 | 0.82 | SMN1; SMN2 (0.43) | LDHASMN1; SMN2SCD5 | |
| SCHEMBL20117144 | 0.82 | USP7 (0.45) | SMN1; SMN2SCD5USP7 | |
| SCHEMBL22358230 | 0.82 | USP7 (0.45) | SMN1; SMN2SCD5USP7KIT | |
| SCHEMBL30506294 | 0.81 | LDHA (0.58) | LDHASMN1; SMN2 | |
| SCHEMBL20116115 | 0.81 | LDHA (0.58) | LDHASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | LDHA 1044/4885SMN1; SMN2 13/4885SCD5 1575/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | LDHA 1044/4885SMN1; SMN2 13/4885SCD5 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.